Bitran J D, Golomb H M, Hoffman P C, Albain K, Evans R, Little A G, Purl S, Skosey C
Cancer. 1986 Jan 1;57(1):44-53. doi: 10.1002/1097-0142(19860101)57:1<44::aid-cncr2820570111>3.0.co;2-h.
Twenty patients with Stage IIIM0 (T3N2) non-small cell lung cancer were treated with vindesine, etoposide, and Platinol (cisplatin) (ELETOP) chemotherapy in an attempt to decrease tumor size and increase resectability and survival. ELETOP chemotherapy induced a 70% response rate (all partial responses) within 6 weeks, and three patients were able to undergo curative resection. Toxicities with ELETOP were moderately severe, with leukocyte and platelet nadirs on day 15. This pilot study demonstrates the feasibility of protochemotherapy in non-small cell lung cancer.
20例IIIM0（T3N2）期非小细胞肺癌患者接受了长春地辛、依托泊苷和顺铂（ELETOP）化疗，以期缩小肿瘤大小，提高可切除性并延长生存期。ELETOP化疗在6周内诱导出70%的缓解率（均为部分缓解），3例患者能够接受根治性切除。ELETOP化疗的毒性为中度严重，白细胞和血小板在第15天降至最低点。这项初步研究证明了术前化疗在非小细胞肺癌中的可行性。
